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ABSTRACT A monoclonal antibody generated against the
decapeptide gonadotropin-releasing hormone (GnRH) was
effective in intercepting the bioactivity of the hormone; it
blocked ovulation in rats. The antibody reacted optimally with
the native hormone. Substitution of amide at the COOH termi-
nus by a carboxyl group decreased immunoreactivity by a fac-
tor of 200. The antibody recognized the amino acid sequences
4-6, 7-10, and 4-10 to a variable degree, which suggests that
the epitope has a conformation involving the entire molecule,
with the NH2- and COOH-terminal regions probably in prox-
imity. The antibody was also competent to suppress the pro-
gression of estrus in dogs, an indication that GnRH may play
an inductive role in the reproductive function of dogs.
Gonadotropin-releasing hormone (GnRH) has a pivotal role
in mammalian reproduction. By regulating the secretion of
follicle-stimulating hormone and luteinizing hormone from
the pituitary, it controls spermatogenesis in the male and
ovulation in the female, with concomitant production of sex
steroids. The hormone is a decapeptide, which has been syn-
thesized along with several analogs having agonistic or an-
tagonistic properties pointing to the portions of the molecule
important for the biological activity of the hormone (1, 2).
Attempts have also been made to map the reading frame-
work of the conventional polyvalent antibodies raised
against the hormone (3, 4). This communication reports the
bioefficacy of a monoclonal antibody generated against the
hormone for block of ovulation in rats. The binding charac-
teristics of this antibody with the entire decapeptide and sub-
peptide fragments have been explored to obtain information
on the topology of the epitope(s) important for bioneutraliza-
tion. A practical use of the antibody is indicated by its ability
to suppress the progression of estrus in dogs.
MATERIALS AND METHODS
Synthetic GnRH (lot IBR5483) was made available by the
Population Council, New York (courtesy Harold Nash and
T. Jackanicz), and by the Center for Population Research,
National Institute of Child Health and Human Development,
National Institutes of Health (courtesy G. Bialy).
Synthesis of GnRH Fragments. The tripeptide (amino acids
4-6), tetrapeptide (amino acids 7-10), and heptapeptide
(amino acids 4-10) of GnRH were synthesized by classical
solution phase methodology. The a-amino group of amino
acids was protected by t-butyloxycarbonyl (Boc). The hy-
droxyl group of serine and tyrosine were protected by benzyl
groups. The guanidine of the arginine was protected by a
nitro group. Coupling was carried out by the dicylohexyl car-
bodiimide-1-hydroxybenzotriazole method. The final con-
densation of tripeptide, Boc-Ser(Bzl)-Tyr(Bzl)-Gly-03zl
with tetrapeptide, H-Leu-Arg(NO2)-Pro-Gly-OBzl, was car-
ried out by the azide procedure (5). The removal of protec-
tion from the Boc group and the nitro and benzyl groups was
done by anhydrous trifluoracetic acid and catalytic hydro-
genolysis, respectively.
Monoclonal Antibody. A number of mouse hybrid cell
clones secreting antibodies binding to GnRH were devel-
oped as described (6). The monoclonal antibody used in this
study was the secretory product of hybrid cell clone P81662.
Hybrid cells were grown as ascites in the intraperitoneal
(i.p.) cavity ofBALB/c mice primed with Pristane (Aldrich).
Ascites fluid tapped from the i.p. cavity was made cell-free
by centrifugation at 800 X g for 15 min at 40C and then heat-
inactivated at 560C for 30 min and centrifuged at 15,000 X g
to remove debris. This ascites fluid, used as a source of anti-
body, had a titer of 106 (i.e., 30%-o40% binding of N251-labeled
GnRH at 106 dilution) in RIA. The antibody was specific to
GnRH. It was devoid of reactivity with thyrotropin-releasing
hormone in competitive RIA. The cross-reactivity (based on
ED50) with GnRH analogs D-Ser (But)6-des-Glyl0-GnRH
ethylamide and Benz-His6-GnRH was lower than with the
native hormone by factors of 387 and 608 (7). The associa-
tion constant (Ka) for binding with GnRH was 1.2 x 109 li-
ters/mol as calculated by Scatchard plot (7). The antibodies
were of IgG2a class with K light chain.
Radioimmunoassay. The reactivity of the hybrid cell prod-
uct with various peptides was determined by competitive
displacement studies in the RIA using 125I-labeled GnRH
and antibody of appropriate dilution to obtain 30%-40%
binding in the absence of competing peptide. lodination of
GnRH (2 pkg) with 1 mCi of carrier-free Na125I (1 Ci = 37
GBq) (Amersham) was carried out as described (3). Over
80% of the labeled hormone was bound in the presence of
excess antibody. The range of specific activity of 1251-la-
beled GnRH was 1400-1600 ,tCi/,ug. Bound 251I-labeled
GnRH was separated by the method of Jeffcoate et al. (8).
Measurement of Heterogeneity Index of the Clonal Product.
The heterogeneity index (a) was calculated by using logarith-
mic transformation of the Sips equation (9)
Blog = a logK + a logFAbt - B
where B is bound hormone, F is free hormone concentration,
and Ab, is antibody binding sites. A plot of log B/(Ab, - B)
versus log F gave a straight line with a slope of heterogeneity
index a; a has a value of 1 for homogeneous or single anti-
body population with respect to antigen-binding affinity.
Ovulation Inhibition. Adult female rats (Holtzman strain),
weighing 200-300 g, were observed for regular cyclicity over
2-3 consecutive estrus cycles and were given 0.5 ml i.p. of
the ascites fluid containing anti-GnRH on the morning (9:00
Abbreviation: GnRH, gonadotropin-releasing hormone.
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FIG. 1. Plot of log (B)/(Ab, - B) vs. log F for heterogeneity in-
dex, a, of the product of clone P81662.
a.m.) of proestrus. Control rats received an equivalent vol-
ume of ascites obtained by growing SP2/0 mouse myeloma
cells. Animals were autopsied the following day (day of es-
trus), and oviducts were flushed for counting of eggs.
Block of Estrus in Female Dogs. Female dogs of mixed
breed were procured locally, dewormed, and kept under ob-
servation in the Institute Animal House. Estrus and its pro-
gression were monitored according to the following criteria;
attraction of male, vaginal swelling, cytology, and receptiv-
ity of the female. Presence of rounded epithelial cells in vagi-
nal smears was interpreted to indicate the proestrus. Estradi-
ol and progesterone in circulation were determined by RIA
(10). Anti-GnRH antibody in ascites fluid, after sterilization
by passage through a Millipore filter (pore size, 0.45 ,um),
was injected intravenously in a single dose of 3.0 ml in dogs
at proestrus.
RESULTS
Evidence for the Monoclonal Nature of the Antibody. The
product of hybrid cell clone P81662 was composed of a homo-
geneous population of antibody. The heterogeneity index, a,
was 1, a result confirming the monoclonal nature of the se-
creted product (Fig. 1).
Bioefficacy of the Monoclonal Antibody. Antibodies against
peptide or steroid hormones are not necessarily of the bio-
neutralizing type. Failure of antibodies, otherwise immuno-
reactive in RIA, to inhibit the biological action of the hor-
mone in vivo has been reported for antibodies against
carboxyl-terminal peptides of j-hCG (human chorionic go-
nadotropin) (11, 12), ,B-TSH (thyrotropic hormone) (13),
and steroids (14). It was, therefore, important to find out
Table 1. Effect of passive administration of monoclonal
anti-GnRH antibody on ovulation in proestrus rats
No. ovulating/ No. of ova
Treatment total (mean ± SEM)
Control 6/6 5.8 ± 0.5
P81662 0/6 0
Ascites fluid (0.5 ml) of clone P81662 was injected i.p. at 9:00 a.m.
on proestrus. Control group received an equivalent amount of asci-
tes fluid devoid of anti-GnRH antibody.
FIG. 2. Competition for binding of '251-labeled GnRH(NH2) with
monoclonal antibody P81662 by GnRH(NH2) (o), GnRH(OH) (o),
GnRH(OH) (amino acids 4-10) (A), GnRH(OH) (amino acids 7-10)
(A), and GnRH(OH) (amino acids 4-6) (n) in RIA. B, radioactivity
bound in presence of labeled GnRH and competing unlabeled pep-
tide. Bo, radioactivity bound with labeled GnRH alone. Values are
expressed as molarity.
whether this monoclonal antibody, directed against a short
peptide, having primarily a single site for binding with the
peptide, had the ability to intercept the biological action of
GnRH. Ovulation being dependent on the luteinizing hor-
mone surge induced by GnRH, the effect on ovulation in rats
was investigated. The anti-GnRH monoclonal antibody giv-
en at proestrus blocked ovulation in all six test animals (Ta-
ble 1).
Binding Characteristics of the Monoclonal Antibody. The
antibody bound best with the native hormone (glycine am-
ide). The analog with the terminal glycine-free carboxyl re-
tained reactivity with the antibody, but the competition was
markedly lower than with the native hormone having amide
at the COOH-terminus. Competition by the tetrapeptide
(Leu-Arg-Pro-Gly-i.e., amino acids 7-10) and tripeptide
(Ser-Tyr-Gly-i.e., amino acids 4-6) with iodinated native
GnRH for binding to the antibody was poor. The heptapep-
tide reacted better with both of the above-mentioned se-
quences than did the individual peptides (Fig. 2). The
amounts of the different peptides needed for achieving 50%
inhibition of binding of native GnRH to monoclonal antibody
are given in Table 2. These results indicate the optimal bind-
ing of the antibody with the entire molecule and suggest that
the reactive topology is contributed to by both the NH2- and
COOH-terminal parts. The proximity of the NH2 terminus to
the COOH terminus of the decapeptide has been indicated in
spectroscopic (15) and computer graphic studies (16).
Suppression of Estrus in Dogs. Dogs usually experience es-
trus twice a year. Information on the endocrinology of dogs
is scanty, and formal evidence is lacking for the presence or
role of GnRH in induction of estrus in the species. Because
Table 2. Amount of peptide needed for 50% inhibition of binding
of 251I-labeled GnRH to monoclonal antibody P81662
Relative reactivity
ED50, M x 103
GnRH(NH2) 1.0 X 10-12 1000.00
GnRH(OH)
(amino acids 1-10) 1.0 x 10-10 10.00
GnRH(OH)
(amino acids 4-10) 2.3 x 10-11 43.60
GnRH(OH)
(amino acids 7-10) 1.7 x 10-9 0.58
GnRH(OH)
(amino acids 4-6) 2.1 x 10-8 0.05
ED50, median effective dose.
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FIG. 3. Normal progression of estrus in female dog treated iLv. with 3 ml of the ascites fluid obtained with mouse myeloma cells (SP2/0) and
devoid of anti-GnRH antibodies.
GnRH does not circulate in amounts high enough to permit
direct assay, even in the mammals in which its role is known,
estimation of the blood level of the hormone in the dogs by
direct RIA was not feasible. Instead, the effect of the mono-
clonal anti-GnRH antibody on estrus was tested in female
dogs given a single intravenous injection of 3.0 ml at proes-
trus.
Fig. 3 illustrates the biological profile during heat of a fe-
male dog that received control ascites fluid obtained by
growing SP2/0 mouse myeloma cells. Fig. 4 typifies the pat-
tern observed in dogs injected with ascites fluid containing
anti-GnRH antibody. Within 48 hr, there was a decrease
both in the receptivity of the female to the male and in the
male's attraction to the female. None of the females pro-
ceeded to estrus; leukocytes were detected within 24-48 hr.
No increase in blood progesterone or estradiol was noted in
the animals receiving anti-GnRH, in contrast to the hormon-
al changes of the control animal approaching estrus (Fig. 3).
The antibody was measurable in circulation for >14 days,
although titers decreased progressively.
DISCUSSION
Interference of the bioactivity of a hormone by antibody de-
mands the prevention by antibody of the binding of hormone
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FIG. 4. Typical effect of administered anti-GnRH monoclonal antibody given to female dogs in the proestrus stage. The antibody sup-
pressed heat within 48 hr as determined by the four criteria listed in the upper part of the figure. The increase in blood progesterone and
estradiol normally occurring during estrus was also prevented. Dashed line shows amount of antibody in circulation on different days after a
single i.v. injection of 3 ml of the ascites fluid of clone P81662.
It
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to the receptor and the subsequent triggering action of the
hormone on the target cell. To achieve this, antibody must
be directed either against the part of the hormone molecule
binding to the receptor or elsewhere in a manner producing
stereochemical constraints on the interaction of the hormone
with the tissue receptors. In situations in which the antibody
fails to impede the hormonal activity in spite of its immuno-
reactivity, as measured by RIA (11-14), it can be speculated
that the antibody is bound to the hormone in a manner dis-
tinct from the requirements for bioneutralization. The low
avidity of the antibodies may also be responsible for incom-
plete scavenging of the hormone as an immune complex (17).
Polyvalent antibodies would, thus, normally have better
properties of bioneutralization of hormonal bioactivity. The
present antibody, which is defined as a monoclonal anti-
body, not only on the grounds of its repeated cloning by lim-
iting dilution but also by its single isotype of heavy and light
chain and the physicochemical properties of monolinear as-
sociation constant, demonstrated the exceptional merits of
intercepting the hormonal activity of GnRH in vivo. The
antibody is directed against a conformation in which both the
NH2- and COOH-terminal regions of GnRH participate, a
postulate consistent with data based on physicochemical and
computer graphic studies (15, 16).
The monoclonal antibodies were effective in blocking ovu-
lation in rats as well as in suppressing the progression of es-
trus in female dogs, as indicated by behavior changes, vagi-
nal cytology, and sex hormonal profiles. These experiments
provide indirect evidence for the involvement of the GnRH
in induction of estrus in this species. Although these antibod-
ies have been used in female animals in the present study, it
can be assumed that they will similarly be active in the male
in blocking events dependent on GnRH.
Mr. K. K. Sarin rendered valuable technical assistance. G.P.T.
thanks the Jawaharlal Nehru Fund for the fellowship, during which
time the monoclonal antibody was generated.
1. Schally, A. V., Arimura, A. & Coy, D. E. (1980) Vitam.
Horm. (N. Y.) 38, 257-323.
2. Rivier, J., Rivier, C., Perrin, M., Porter, J. & Vale, W. W.
(1981) in LHRH Peptides as Female and Male Contraceptives,
eds. Zatuchni, G. I., Shelton, J. D. & Sciarra, J. J. (Harper &
Row, Philadelphia), pp. 13-23.
3. Copeland, K. C., Aubert, M. L., Rivier, J. & Sizonenko, P. C.
(1979) Endocrinology 104, 1504-1512.
4. Arimura, A., Sato, H., Coy, D. H., Worobee, R. B., Schally,
A. V., Yanaihara, N., Hashimoto, T., Yanaihara, C. & Sa-
kura, N. (1975) Acta Endocrinol. (Copenhagen) 78, 222-231.
5. Hirschmann, R. & Veber, D. F. (1969) J. Am. Chem. Soc. 91,
507-508.
6. Gupta, S. K. & Talwar, G. P. (1983) in Non-Isotopic Immuno-
assays and their Applications, ed. Talwar, G. P. (Vikas,
Delhi, India), pp. 127-135.
7. Gupta, S. K., Singh, 0. & Talwar, G. P. (1984) Am. J. Reprod.
Immunol., in press.
8. Jeffcoate, S. L., Fraser, H. M., Holland, D. T. & Gunn, A.
(1974) Acta Endocrinol. (Copenhagen) 75, 625-635.
9. Sips, R. (1948) J. Chem. Phys. 16, 490-495.
10. (1980) Programme for the Provision of Matched Assays Re-
agents for the Radioimmunoassays ofHormones in Reproduc-
tive Physiology, Method Manual. (World Health Organization,
Geneva, Switzerland).
11. Louvet, J. P., Ross, G. T., Birken, S. & Canfield, R. E. (1974)
J. Clin. Endocrinol. Metab. 39, 1155-1158.
12. Matsuura, S., Ohashi, M., Chen, H. C. & Hodgen, G. D.
(1979) Endocrinology 104, 396-401.
13. Beall, G. N., Chopra, I. J., Solomon, D. J., Pierce, J. C. &
Cornell, J. S. (1973) J. Clin. Invest. 52, 2979-2985.
14. Vecsei, P., Haack, D. & Gless, K. H. (1979) in Antihormones,
ed. Agarwal, M. K. (Elsevier/North-Holland, Amsterdam),
pp. 17-34.
15. Donzel, B., Rivier, J. & Goodman, M. (1977) Biochemistry 16,
2611-2618.
16. Momany, F. A. (1976) J. Am. Chem. Soc. 98, 2990-2996.
17. Ramakrishnan, S., Das, C., Dubey, S. K., Salahuddin, M. &
Talwar, G. P. (1979) J. Reprod. Immunol. 1, 249-261.
Medical Sciences: Talwar et aL
